IRVINE, Calif.--(BUSINESS WIRE)--Feb 19, 2013--Presbia, a medical device company and leader in near vision restoration, announced today the appointment of Jake Vander Zanden as Chief Commercial Officer. Bringing more than 25 years of experience in the healthcare industry, Mr. Vander Zanden will be responsible for expanding the commercial growth of the Presbia Flexivue Microlens™, the company’s implantable corneal inlay solution for presbyopia, the age-related loss of near vision.

“Jake’s extensive experience in the ophthalmology space will be extremely valuable to Presbia as we continue to ramp up our efforts to grow the commercial availability of the Presbia Flexivue Microlens™ outside of the United States,” said Zohar Loshitzer, Chief Executive Officer of Presbia. “By adding top talent and resources to these efforts, we hope to be able to accelerate market availability of our innovative solution for the correction of near vision loss to an even greater number of patients.” Mr. Vander Zanden has served in top positions at major global corporations focused on ophthalmology. Most recently, he served as President of the Americas at Hoya Surgical Optics, a manufacturer of ophthalmic intraocular lenses (IOLs) based in Singapore. He has also served as Corporate Vice President, SVP & General Manager at Lumenis, Inc., a manufacturer of ophthalmic lasers, and as Vice President and General Manager, Global Pain Management at Medtronic Neurological, and has held senior leadership roles in multiple international assignments with Allergan, Inc., a multi-specialty healthcare company focused on pharmaceuticals, biologics, medical devices and over-the-counter consumer products. He serves on the Board of Directors of Prevent Blindness America, and the Board of Advisors for the Sand Hill Incubator.

“The Presbia Flexivue Microlens™ offers a truly innovative solution for presbyopia, a condition that affects so many people around the world, and I am excited to join the Presbia team and lead the efforts to broaden its commercial availability,” said Mr. Vander Zanden.

Presbia submitted its Investigational Device Exemption request with U.S. Food & Drug Administration in September 2012 for the Presbia Flexivue Microlens™. The lens received the CE Mark in 2009, and today it is widely available commercially in Europe, Latin America, the Middle East and Asia.

Presbia is a leading ophthalmic-device company focused on the development of solutions for presbyopia, the age-related loss of the ability to read or focus on near objects. Chief among these approaches is the Presbia Flexivue Microlens™, a 3mm-diameter lens that is implanted in the corneal stroma of the patient’s non-dominant eye using femtosecond laser technology. The procedure requires no general anesthesia, and the patient’s visual recovery typically takes only a couple of days. Since the Presbia Flexivue Microlens™ solution utilizes standard equipment and requires minimal additional training, the procedure requires no significant capital investment by the surgeon’s practice.

Further information is available at